Skip to main navigation
  • Contact Us
Xen 01
  • About Us
    • Management
    • Partnering
    • Board of Directors
  • Pipeline
    • XmAb819 (ENPP3 x CD3)
    • XmAb808 (B7-H3 x CD28)
    • XmAb541 (CLDN6 x CD3)
    • Plamotamab (CD20 x CD3)
    • XmAb942 (Xtend TL1A)
    • XmAb657 (CD19 x CD3)
  • Technology
    • Bispecific Fc Domains
    • Cytotoxic Fc Domains
    • Immune Inhibitor Fc Domains
    • Xtend Fc Domains
    • Publications
  • Clinical Trials
    • Expanded Access Policy
  • Investors
    • Investors
    • Press Releases
    • Events & Presentations
    • Corporate Governance
      • Management
      • Board of Directors
      • Committee Composition
      • Contact the Board
    • Financials & Filings
      • SEC Filings
      • Annual Reports
    • Analyst Coverage
    • Stock Information
      • Historic Stock Lookup
      • Investment Calculator
    • Investor FAQs
    • Contact Us
    • Email Alerts
  • Careers

You are here:
Home / Investors / / Xencor ESMO 2026 Webcast: XmAb819 Phase 1 Dose Expansion Cohort Results

Investor Relations

  • Investors
  • Press Releases
  • Events & Presentations
  • Corporate Governance
  • Financials & Filings
  • Analyst Coverage
  • Stock Information
  • Investor FAQs
  • Contact Us
  • Email Alerts

Tools

Shareholder Tools

  • Snaphot
  • Print
  • Share
  • Facebook
  • LinkedIn
  • Twitter
  • RSS

Xencor ESMO 2026 Webcast: XmAb819 Phase 1 Dose Expansion Cohort Results

Oct 26, 2026 at 7:00 AM EDT

Add to Outlook
Add to Google Calendar
Listen to webcast
Xencor © Copyright 2026 | Privacy Policy
Scroll to top